8/25/2020 7:06:11 AM
Takeda Pharma: Phase 2 ELEKTRA Study Of Soticlestat Meets Primary Endpoint
7/13/2020 9:04:02 AM
Ovid And Angelini To Develop, Manufacture And Commercialize OV101 For Treatment Of Angelman Syndrome In Europe
7/13/2020 7:06:35 AM
Ovid Therapeutics, Angelini Pharma Enter Exclusive License Agreement To Develop OV101
6/19/2020 8:05:15 AM
Ovid Therapeutics Secures FDA Rare Pediatric Disease Designation For OV101
5/7/2020 7:47:36 AM
Ovid Says OV101 Met Study's Primary Objective Of Safety And Tolerability
11/18/2019 4:08:55 PM
Ovid Therapeutics Appoints Jason Tardio As Chief Commercial Officer
10/4/2019 8:34:40 AM
Ovid Therapeutics Prices $32.5 Mln Of Securities In Concurrent Public Offerings Of Common Stock And Preferred Stock
9/23/2019 7:07:58 AM
Ovid Therapeutics Announces Positive Initial Data From Ongoing ENDYMION Open-Label Extension Trial Of Soticlestat
7/2/2019 8:15:37 AM
Ovid Therapeutics Gets Orphan Drug Designation From European Commission For OV101 For Angelman Syndrome